Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.
about
Dangerous liaisons: molecular basis for a syndemic relationship between Kaposi's sarcoma and P. falciparum malariaKSHV reactivation and novel implications of protein isomerization on lytic switch controlKaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON TB-Gold interferon-gamma assayClinical characteristics and outcomes of HIV-infected children diagnosed with Kaposi sarcoma in Malawi and Botswana.Surgical Management of Unicentric Castleman's Disease in the Abdomen.Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment.Regulation of CD1d expression and function by a herpesvirus infection.A computational profiling of changes in gene expression and transcription factors induced by vFLIP K13 in primary effusion lymphomaCarcinogenic viruses and solid cancers without sufficient evidence of causal association.Induction of angiogenic chemokine CCL2 by human herpesvirus 8 chemokine receptor.Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma.Epstein-Barr virus-associated lymphomas.KSHV/HHV8-associated lymphomas.Molecular biology of KSHV lytic reactivation.Metastatic Kaposi's Sarcoma with Perirectal Involvement Diagnosed with Endoscopic Ultrasound-Guided EchoBrush Cytology Sampling.Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells.Differentially regulated splice variants and systems biology analysis of Kaposi's sarcoma-associated herpesvirus-infected lymphatic endothelial cells.Castleman's disease: systematic analysis of 416 patients from the literatureImmunohistochemical and molecular assessment of human herpesvirus type 8 in gastrointestinal tumoursKSHV/HHV-8 and HIV infection in Kaposi's sarcoma development.Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors.KSHV-Mediated Regulation of Par3 and SNAIL Contributes to B-Cell ProliferationHerpesviruses in periodontal diseases.Kaposi's sarcoma-associated herpesvirus: clinical, diagnostic, and epidemiological aspects.Localised plasma-cell type Castleman's disease and AA-amyloidosis cured by resection. A case report and review of the literature.Role of infectious agents in the carcinogenesis of brain and head and neck cancers.Pulmonary complications of HIV infection.EBV reactivation as a target of luteolin to repress NPC tumorigenesis.The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5Upregulation of human β-defensin-3 and cathelicidin LL-37 in Kaposi's sarcomaValganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cellsThe malignant potential of HIV-associated Kaposi sarcoma.Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.The role of stromal-derived factor-1--CXCR7 axis in development and cancer.Castleman disease in a pediatric liver transplant recipient: a case report and literature review.Molecular diagnostics of non-Hodgkin lymphoma.Skin cancer in kidney transplant recipients.
P2860
Q21131129-C6E60E91-F967-487E-A354-33A4150CBD14Q28080937-820472B8-B481-4D61-A0E5-84DF95123177Q28296088-5579F64F-4BA7-4AB6-8C0C-2A4A76FD4B44Q33221441-AEB845DE-A35E-487F-A0BF-A18B0770FF16Q33325633-82E604A8-FD6B-4E0B-93A3-3A1F4847A9A5Q33406437-AE474CB0-643C-45ED-AF98-3282D3AD4BF9Q33618927-6114370A-ABB2-433A-99EA-C330B2E8BE51Q33760703-4846F748-5318-4A69-A028-9F4AE482A8A3Q33768331-B6D2714F-1A94-48D5-B9D1-0C6E5A942512Q34280032-1FE47B49-E7E4-4C8B-90BC-2F50D843CBF0Q34320412-E9EEF5F9-E61C-4099-BE1C-D9FD300386A7Q34508261-43FD23C2-1FBB-4A29-8503-3D59441BBF42Q34587349-E72AE466-80C4-464B-ACE3-1C416E6AA801Q34651670-E2FE17C3-5B92-4660-A5E8-AA1B3AB970A7Q34711929-5D62E07C-8748-4701-B48C-94DC5C3B09A6Q35014918-E60716E0-2479-4EE3-8E31-E0E01EE4D695Q35149879-2423123F-A0DE-40FE-9306-101660D1AA70Q35150054-4B07E6DB-ED45-4D18-90C9-0A692681152EQ35198402-FD0F655C-ED80-47CF-8325-1FEF31C22DC2Q35584758-959BD1C7-2AC9-48CB-9929-9DCBB9C00484Q35589049-208B490C-4F54-44A5-B74F-5DC56EE24836Q35642220-A81C0A94-284A-4BF5-9075-C03952FC183DQ35911472-A66943EB-ACDA-40D3-97C3-833089F7A498Q36087231-059470B5-B967-4BD9-8235-9FCAC39010BDQ36107779-EDB450BF-23F2-40F0-A36A-BA810F5D3540Q36154559-2B2CCF87-95C0-4931-AC52-AB2E3A11392BQ36176197-6792C3C3-3D26-4A58-9A0D-C79B1A860E8FQ36614198-4C044CEA-EB22-484D-8134-1AB58D617301Q37109551-53F65E94-D44F-4B52-B6B4-9C41102386B2Q37109915-CC21369B-9664-4C33-9A95-C3D49E4528A7Q37136785-32EE7533-B268-4403-BA68-15C14D5819FCQ37195726-67DBF0BB-6029-4BB3-A988-5D95FDD133B0Q37237122-BB1817E6-868D-45E5-BA95-E383DDA69234Q37288834-8765C462-D190-41DA-B768-AE19D431269BQ37314351-A8343D05-294D-4ECF-BD19-B5E0677915B4Q37348174-7155CF7F-B0C5-42B2-862D-1FCD3EEF99C0Q37616298-59F2BF07-17BC-475C-AB73-A5C6B046A6C5Q37950123-B65E8D53-05F1-45E6-AD54-FABE2FBD04DEQ38089227-6392C2B3-FD4B-433C-9A06-462C63CE6667Q38210273-3446FC74-0887-4BD6-953F-82FF899CE88B
P2860
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@ast
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@en
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@nl
type
label
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@ast
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@en
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@nl
prefLabel
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@ast
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@en
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@nl
P2093
P1476
Update on Kaposi's sarcoma and ...... and pleural effusion lymphoma.
@en
P2093
Martin Stuschke
Michael Roggendorf
Robert A Schwartz
Siegfried Seeber
Stephen K Tyring
Thomas Ruzicka
Ulrich R Hengge
P304
P356
10.1016/S1473-3099(02)00288-8
P577
2002-06-01T00:00:00Z